Kamel, Hooman
Bartz, Traci M.
Longstreth, W. T. Jr.
Elkind, Mitchell S. V.
Gottdiener, John
Kizer, Jorge R.
Gardin, Julius M.
Kim, Jiwon
Shah, Sanjiv
Article History
Received: 25 May 2021
Accepted: 11 August 2021
First Online: 30 August 2021
Competing interests
: Drs. Elkind, Kamel, and Longstreth serve as PIs for the NIH-funded ARCADIA trial which receives in-kind study drug from the BMS-Pfizer Alliance and ancillary study support from Roche Diagnostics. Dr. Kamel serves as a steering committee member of Medtronic’s Stroke AF trial (uncompensated), serves on an endpoint adjudication committee for a trial of empagliflozin for Boehringer-Ingelheim, and has served on an advisory board for Roivant Sciences related to Factor XI inhibition. Dr. Elkind receives royalties from UpToDate for chapters related to cryptogenic stroke and other topics. Dr. Shah has received research grants from Actelion, AstraZeneca, Corvia, Novartis, and Pfizer; and has received consulting fees from Abbott, Actelion, AstraZeneca, Amgen, Axon Therapeutics, Bayer, Boehringer-Ingelheim, Boston Scientific, Bristol-Myers Squibb, Cardiora, CVRx, Cytokinetics, Edwards, Eisai, GSK, Ionis, Ironwood, Imara, Lilly, Merck, MyoKardia, Novartis, Novo Nordisk, Pfizer, Regeneron, Sanofi, Shifamed, Tenax, and United Therapeutics. The other authors report no competing interests.